II. Definitions
- Optic Neuritis
- Inflammation of the Optic Nerve
III. Epidemiology
- Incidence: 1 to 5 per 100,000 in U.S. per year
- Age in typical Optic Neuritis (demyelinating)
- Young patients predominate (esp. age 20 to 45 years old)
- Most common cause of unilateral Vision Loss in young adults
IV. Types: General
- Typical Optic Neuritis (Demyelinating, most common)
- Classic triad: Unilateral Vision Loss, painful Extraocular Movement, impaired color Vision
- Relative Afferent Pupillary Defect, and typically normal fundoscopic exam (or mild optic disc swelling)
- Progresses over days to weeks, and then, regardless of treatment, spontaneously resolves in 90% of cases
- Associated with Multiple Sclerosis (or idiopathic)
- Immune-mediated inflammatory demyelination of the Optic Nerve
- Demyelination results in Retinal Ganglion cell axon degeneration
- Atypical Optic Neuritis (not MS associated)
- More common in males, age <18 years or over 50 years old
- Broad list of potential causes (see below) unrelated to Multiple Sclerosis
- Presents with bilateral, acute, painless Vision Loss that progresses over 2 weeks and persists
- Severe Vision Loss (20/200 or worse)
- Severe optic disc swelling
V. Types: Specific Atypical Optic Neuritis Demyelinating Syndromes (Uncommon)
-
General
- Rare CNS inflammatory disorders distinct from Multiple Sclerosis (MS)
- Among the atypical Optic Neuritis causes
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Presents with severe Vision Loss (20/400 or worse), often bilateral
- Residual deficits are worse with delay in Glucocorticoid treatment
- Aquaporin-4 (AQP4) serum Antibody positive AND at least 1 of the following clinical features
- Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis (MOG-IgG Optic Neuritis)
- Severe, Acute Vision Loss on presentation (often recurrent attacks)
- Optic disc edema is present in all patients
- Much better longterm prognosis than NMOSD
- MOG-IgG Optic Neuritis final Vision is typically 20/30
VI. Causes
- Demyelinating Conditions (see above)
- Multiple Sclerosis (typical Optic Neuritis)
- Optic Neuritis is the presenting finding in 15-20% of Multiple Sclerosis (overal seen in 50% of MS cases)
- Uncommon, atypical demyelinating causes
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis (MOG-IgG Optic Neuritis)
- Multiple Sclerosis (typical Optic Neuritis)
- Autoimmune Conditions
- Infections (rare)
- Lyme Disease
- Syphilis
- HIV Infection
- Tuberculosis
- West Nile Virus
- Toxpolasmosis
- Fungal infections
- Encephalomyelitis
- Optic Nerve vascular lesions
- Tumor
- Optic Nerve glioma
- Neurofibromatosis
- Meningioma
- Medications
VII. Risk Factors: Typical Optic Neuritis
- Multiple Sclerosis
- White Race
- Female Gender
- Age 20 to 45 years old
VIII. Symptoms: Typical Optic Neuritis
- Pain behind affected eye is variably present
- Worse with eye movement
- Central Vision Loss
- Loss of color Vision
- Impaired Vision develops over hours to days
- Affects one or both eyes
- Rarely results in total blindness
- Acuity often worse than 20/100
IX. Signs: Typical Optic Neuritis
- Unilateral optic disc swelling and blurring of the disc margin
- Optic Nerve pallor, hyperemia or Papillitis present (Papilledema)
- Optic disc may appear normal in Retrobulbar Optic Neuropathy
- Pupil light reflex abnormal
- Provocative maneuvers
- Extraocular Movement painful
- Pressure on globe painful
- Decreased Visual Acuity amd Visual Field Deficits
X. Labs
- Atypical Optic Neuritis Demyelinating Conditions (Uncommon)
- Aquaporin-4 (AQP4) serum Antibody (NMOSD)
- Myelin Oligodendrocyte Glycoprotein IgG (MOG-IgG Optic Neuritis)
- Cerebrospinal Fluid
- Consider in findings suggestive of MS and typical Optic Neuritis
- Typical Optic Neuritis MS-related findings
- WBC: Normal or 10-20 WBC present
- Oligoclonal bands may be present
XI. Imaging
-
Brain MRI and Orbit MRI with gadolinium contrast (and spine in NMOSD)
- Typical Optic Neuritis is a clinical diagnosis based on history and exam, and does not require MRI
- MRI may confirm acute demyelinating Optic Neuritis (Optic Nerve enhancement)
- MRI may show concurrent CNS findings of Multiple Sclerosis (e.g. periventricular white matter deficits)
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Obtain MRI Brain and spinal cord with gadolinium contrast
- Optic Nerve lesions (involving >50%), often bilateral, and may involve Optic Chiasm
- Spine may demonstrate extensive Transverse Myelitis (>3 levels) and central cord involvement
- Contrast with typical Optic Neuritis of MS, in which the peripheral spinal cord is involved
- Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis (MOG-IgG Optic Neuritis)
- Extensive Optic Nerve enhancement on MRI Brain, with no other Brain Lesions (unlike MS)
- Typical Optic Neuritis is a clinical diagnosis based on history and exam, and does not require MRI
XII. Differential Diagnosis
XIII. Management: Typical Optic Neuritis
- Hospital admission
- IV Glucocorticoids
- Methylprednisolone 250 mg IV every 6 hours (or 1 g daily) for 3 days
- May be followed by oral Corticosteroid course
- Efficacy
- May reduces chance of future Multiple Sclerosis
- Corticosteroids speed Vision recovery in typical Optic Neuritis
- However, Corticosteroids appear to offer no benefit at 6 months in typical Optic Neuritis
- Avoid low dose Corticosteroid (no benefit, and higher relapse risk)
- Gal (2015) Cochrane Database Syst Rev (8): CD001430 [PubMed]
XIV. Management: Atypical Optic Neuritis
- Indications
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis (MOG-IgG Optic Neuritis)
- Acute Optic Neuritis
- Methylprednisolone 1 g IV daily for 5 days, then oral steroid taper
- Best outcomes with early treatment (esp. for NMOSD)
- Plasma Exchange
- Indicated in refractory cases
- Methylprednisolone 1 g IV daily for 5 days, then oral steroid taper
- Chronic Immunosuppression to prevent relapse
XV. Course
- Isolated, typical Optic Neuritis
- Up to 30-50% develop Multiple Sclerosis within 15 years
XVI. References
- Yanoff (1999) Ophthalmology, Mosby, p. 6.2-6.4
- Yu and Jasani (2024) Crit Dec Emerg Med 38(1): 27-34